Thw

PTO/SB/21 (05-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)-

Application Number	10/632,706	
Filing Date	August 1, 2003	
First Named Inventor	James D. Marks	
Group Art Unit	1645	
Examiner Name	Virginia Allen Portner	
Attorney Docket Number	407T-895120US	

10/7/05

Date

Total Nulliber o	n rages in This oubin	1331011		Attorney Docket No	ullibel		10/1 0/012000	
ENCLOSURES (check all that apply)								
Fee Transm	ittal Form			nent Papers Application)			After Allowance Communication to Group	
Fee A	Attached		Drawing	(s)		***************************************	Appeal Communication to Board of Appeals and Interferences	
Amendmen	at / Response		Licensin	g-related Papers	[Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
Afte	r Final		Petition and Acc	Routing Slip (PTO/SB/ ompanying Petition	/69)		Proprietary Information	
Affic	davits/declaration(s)			to Convert to a nal Application	1		Status Letter	
Extension of	of Time Request		Power o Change Address	f Attorney, Revocation of Correspondence	·	Χ	Additional Enclosure(s) (please identify below):	
	Express Abandonment Request X Information Disclosure Statement		Terminal Disclaimer Small Entity Statement				2 Enclosed Reference receipt acknowledgment postcard	
Certified Condition Document(Response Incomplete Response Part 1.52	Please this par for con	rization to charge Deper or duri	t for Refund Charge Deposit Acceposit Acceposit Account No. 50-ing the pendency of this of the documents encl	0893 for s applica	r any	additional fees associated with including any extensions of time		
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm <i>or</i> Individual name	Tom Hunter, Re						Property Law Group P.C.	
Signature Um M								
Date	October 7, 200	5	U					
CERTIFICATE OF MAILING								
I hereby certify that this cor envelope addressed to: Co	respondence is being facsimile t mmissioner for Patents, P.O. Bo	ransmitted	to the USPTO		tates Postal	Servi	ce with sufficient postage as first class mail in an 2005	

1

Typed or printed name

Signature

ndence is being

I hereby cold deposited with the URAS States Postal Service first class mail in an envelope addressed to: Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450, on October 7, 2005

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

Attorney Docket No. 407T-895120US Client Ref. No. 1998-013-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

James D. Marks, et al.

Application No.: 10/632,706

Filed: August 1, 2003

For: THERAPEUTIC MONOCLONAL

ANTIBODIES THAT NEUTRALIZE

BOTULINUM NEUROTOXINS

Confirmation No.

Examiner: Virginia Allen Portner

Art Unit: 1645

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

§ 1.98

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also, enclosed is a copy of International Search Report for corresponding International Application No. PCT/US03/24371. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

James D. Marks, et al.

Application No.: 10/632,706

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Tom Hunter, J.D., Ph.D.

Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

P.O. BOX 458

Alameda, CA 94501

(510) 337-7871

Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons ar		PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031 I Trademark Office; U.S. DEPARTMENT OF COMMERCE nformation unless it contains a valid OMB control number.		
Substitute for form 1449A-B/PTO	Complete if Known			
INFORMATION DISCLOSURE	Application Number	10/632,706		
INFORMATION DISCLOSURE	Filing Date	August 1, 2003		
STATEMENT BY APPLICANT 1 2005	First Named Inventor	James D. Marks		
	Group Art Unit	1645		
	Examiner Name	Virgina Allen Portner		
(use as many sheets as the essary)	Attorney Docket Number	407T-895120US		
A STAND	Date Submitted	October 7, 2005		

	l	U.S. Patent Document		Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appea
	1	2004/0265935 A1		Atassi	12/30/2004	
	2	2004/0175385 A1		Marks et al.	09/09/2004	

				FOREIG	N PATENT DOCUMEN	TS		
	Foreign Patent Document		nent		Date of Publication	Pages, Columns, Lines,	Γ	
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T
				1				\vdash
				+				\vdash
								igapha
				1				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
	3	HALL (2004) Journal of Immunological Methods 288, pp. 55-60	
	4	OSHIMA (1997) Molecular Immunology Vol. 34, No. 14, pp. 1031-1040	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.